UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
ANAVEX LIFE SCIENCES CORP. |
|
(Name of Issuer) |
|
Common Shares with a par value of $0.001 |
|
(Title of Class of Securities) |
|
032797102 |
|
(CUSIP Number) |
|
copy to: | |
|
Harvey Lalach (250) 764-9701 |
Clark Wilson LLP |
|
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) | |
|
July 30, 2007 |
|
(Date of Event which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ].
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
CUSIP No. |
032797102 |
|
1 |
NAMES OF REPORTING PERSONS | |||
|
Athanasios Skarpelos | ||||
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | |||
|
(a) o (b) o | ||||
|
3 |
SEC USE ONLY | |||
|
| ||||
|
4 |
SOURCE OF FUNDS (See Instructions) | |||
|
PF | ||||
|
5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) | |||
|
[ ] | ||||
|
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION | |||
|
Greek | ||||
|
NUMBER OF |
7 |
SOLE VOTING POWER |
| |
|
8,425,000 common shares |
| |||
|
8 |
SHARED VOTING POWER |
| ||
|
N/A |
| |||
|
9 |
SOLE DISPOSITIVE POWER |
| ||
|
8,425,000 common shares |
| |||
|
10 |
SHARED DISPOSITIVE POWER |
| ||
|
N/A |
| |||
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||
|
8,425,000 common shares | ||||
|
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | |||
|
[ ] | ||||
|
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |||
|
43.8% based on 19,200,000 common shares issued and outstanding as of July 12, 2007 | ||||
|
14 |
TYPE OF REPORTING PERSON (See Instructions) | |||
|
IN | ||||
Page 2
|
Item 1. |
Security and Issuer |
This Statement relates to common shares with a par value of $0.001 of ANAVEX LIFE SCIENCES CORP. (the “Issuer”). The principal executive offices of the Issuer located at 101-4837 Canyon Ridge Crescent, Kelowna, BC V1W 4A1.
|
|
Item 2. |
Identity and Background |
| |||
|
|
(a) |
Athanasios Skarpelos | ||||
|
|
(b) |
14 Rue Kleberg CH-1201, Geneva Switzerland. | ||||
|
|
(c) |
Mr. Skarpelos is a self-employed businessman. | ||||
|
|
(d) |
Mr. Skarpelos has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years. | ||||
|
|
(e) |
Mr. Skarpelos has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction where, as a result of such proceeding, there was or is a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. | ||||
|
|
(f) |
Mr. Skarpelos is a citizen of Greece. | ||||
|
|
Item 3. |
Source and Amount of Funds or Other Considerations |
| |||
Mr. Skarpelos acquired beneficial ownership on April 25, 2006 of 1,562,500 by way of a cash purchase using personal funds. Pursuant to a 6:1 stock split, Mr. Skarpelos then owned 9,375,000 common shares.
On July 30, 2007, Mr. Skarpelos sold 950,000 common shares and now owns 8,425,000 common shares.
Item 4. Purpose of Transaction
Mr. Skarpelos purpose of the original transaction was for personal investment and to acquire control of the Issuer. Currently, Mr. Skarpelos now holds 8,425,000 common shares.
Mr. Skarpelos reserves the right to actively pursue various proposals which could relate to or would result in:
|
|
(a) |
the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; |
|
|
(b) |
an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; |
|
|
(c) |
a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; |
|
|
(d) |
any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; |
Page 3
|
|
(e) |
any material change in the present capitalization or dividend policy of the Issuer; | ||||
|
|
(f) |
any other material change in the Issuers business or corporate structure; | ||||
|
|
(g) |
changes in the Issuers charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; | ||||
|
|
(h) |
causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; | ||||
|
|
(i) |
a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; and | ||||
|
|
(j) |
any action similar to any of those enumerated above. | ||||
|
|
Item 5. |
Interest in Securities of the Issuer |
| |||
|
|
(a) |
As of July 30, 2007, the aggregate number and percentage of common shares of the Issuer beneficially owned by Athanasios Skarpelos is 8,425,000 common shares, or approximately 43.8% of the Issuer. |
| |||
|
|
(b) |
Mr. Skarpelos has the sole power to vote or direct the vote, and to dispose or direct the disposition, of 8,425,000 shares of common stock of the Issuer. |
| |||
|
|
(c) |
Other than as described in Item 3 above, Mr. Skarpelos has not effected any transaction in the shares of common stock of the Issuer in the past 60 days. |
| |||
|
|
(d) |
N/A |
| |||
|
|
(e) |
N/A |
| |||
|
Item 6. |
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer |
Except as set forth above or set forth in the exhibits, there are no contracts, arrangements, understandings or relationships between Reporting Persons and any other person with respect to any securities of the Issuer.
|
Item 7. |
Material to Be Filed as Exhibits |
Affiliate Stock Purchase Agreement dated April 25, 2006 (incorporated by reference to my Schedule 13D filed on April 28, 2006).
Page 4
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
July 30, 2007 |
|
|
Dated |
|
|
/s/ Athanasios Skarpelos |
|
|
Signature |
|
|
Athanasios Skarpelos |
|
|
Name/Title |
|
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).